Psychedelics has become one of the hottest industries in biotech. Research and Markets recently estimated that the psychedelic drugs market will reach $10.75 billion by 2027. Big investors like Peter Thiel, Kevin O'Leary, and even former pot industry trailblazers have started to place their bets. The name of the game right now is R&D. There will be some huge winners in this growing industry over the next few months.
NEW ENTRANT TO THE MARKET: RLBD
-Real Brands (OTCMKTS: RLBD) applying for DEA psychedelics licensure
Real Brands (OTCMKTS: RLBD) just announced it is to become a premier provider of medical psychedelics. As Phase 1 of laying the groundwork for entry into the medical psychedelics market, Real Brands has entered a partnership with consulting firm Marcu & Arora to apply for U.S. Drug Enforcement Agency (DEA) licensure for psychedelics, including defining the protocols for application and the focus of the formulation research and development. Additionally, Real Brands will apply to the DEA for authorization to process and handle psychedelic substances, and it has applied to the state of Rhode Island to be able to prescribe, dispense, store and ship controlled substances.
"We are pursuing research and development of medical psychedelics because current traditional mental health care treatments are often ineffective and have severe negative side effects," stated Thom Kidrin, CEO of Real Brands. "Revolutionary breakthroughs in medicine, pharmacology, and behavioral neuroscience have exposed the vast potential of psychedelics and empathogenic drugs as highly effective therapies. We have engaged Marcu & Arora to help us navigate the complicated process of DEA licensure for research on psychedelics, the protocols for application and all aspects of formulation R&D. We hope to become the first in Rhode Island to secure a license."
Kidrin noted, "Dr. Jahan Marcu and Dr. Nigam B. Arora are two of the most knowledgeable experts in the fledgling psychedelics industry. With a combined 30+ years of experience in chemistry, pharmacology, research, communications, government relations, advocacy, and entrepreneurship, we believe their ability to navigate the federal regulatory and research environments are unparalleled. Additionally, Marcu & Arora's network of PhD scientists, medical doctors, attorneys, standards experts and venture capital firms specializing in these areas provides us with additional resources we can tap to efficiently build our psychedelics business with the highest standards."
Havn Life Sciences (OTCMKTS: HAVLF) is ran by former CEO of Aphria, Vic Neufeld sitting as the Executive Chairman of Havn. Under his direction, Aphria became one of the top names in cannabis just as the industry was getting off the ground. Some psychedelic companies are simply growing mushrooms and selling inconsistent products. Havn Life has gone above and beyond to create a gold standard of psychedelic and new age, natural health products.
Havn (OTCMKTS: HAVLF) aims to supply as many researchers as it can with naturally derived compounds. This partnership could bring it one step closer to this goal of building an international psychedelic supply chain framework.
MindMed (OTCMKTS: MMEDF) has developed a novel platform for psychedelic-assisted treatments. Last quarter, the company completed the acquisition of HealthMode. They utilize AI to enable digital measurement & ultimately increase the precision and speed of clinical research & patient monitoring. This acquisition marked the start of the company's "MindMed 2.0," building a mental health tech platform. CEO J.R. Rahn explained that "In effect, we see a future mental health treatment paradigm where potential drug products such as our LSD experiential therapy might be prescribed right alongside software application programming interfaces (APIs) to prepare the patient for treatment and optimally monitor the after-care of one's anxiety disorder."
Seelos Therapeutics (NASDAQ: SEEL) just entered into an amendment to a 3-year old agreement with Vyera Pharmaceuticals to repurchase a significant portion of the royalties payable on future sales of SLS-002.
Management said that this should return "meaningful" future value to shareholders. Since there's a current study of SLS-002 going through patient dosing right now, it could be a time to follow Seelos. The last patient was expected to complete Part 1 of the study this week. Open-label could come out this quarter according to Seelos.
Cybin Inc. (NYSE: CYBN) is a Canadian pharmaceutical company developing psychedelic medicines for the treatment of mental illnesses such as depression, anxiety and addiction. The company's clinical-stage EMBARK trial is testing psilocybin in treating mental distress of front-line health care workers. In May 2021, Cybin was approved to begin Phase 2 clinical trials of CYB001 in treating major depressive disorder, or MDD. In November, Cybin reported positive pre-clinical findings for its CYB003 deuterated psilocybin analog in treating alcohol use disorder and MDD. Cybin recently partnered with popular author and alternative medicine advocate Deepak Chopra to raise awareness of the potential for psychedelics to support well-being and mental health.
Disclaimers: Capital Gains Report 'CGR' is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by CGR is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall CGR. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by CGR., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. CGR. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, CGR., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated fifteen thousand dollars via wire transfer by Washington Capital to produce and syndicate content for RLBD. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
CONTACT: To educate and attract more investors contact us at:
Mark McKelvie
editorcapitalgainsreport@gmail.com
(754) 233-0966
.
SEELOS THERAPEUTICS, INC. 
